Andrea Visentin1, Silvia Imbergamo2, Carmela Gurrieri2, Federica Frezzato1, Valentina Trimarco1, Veronica Martini1, Filippo Severin1, Flavia Raggi1, Edoardo Scomazzon2, Monica Facco1, Francesco Piazza1, Gianpietro Semenzato3, Livio Trentin4. 1. Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Italy; Venetian Institute of Molecular Medicine, Centro di Eccellenza per la Ricerca Biomedica Avanzata, Italy. 2. Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Italy. 3. Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Italy; Venetian Institute of Molecular Medicine, Centro di Eccellenza per la Ricerca Biomedica Avanzata, Italy. Electronic address: g.semenzato@unipd.it. 4. Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Italy; Venetian Institute of Molecular Medicine, Centro di Eccellenza per la Ricerca Biomedica Avanzata, Italy. Electronic address: livio.trentin@unipd.it.
Abstract
BACKGROUND: Major infections (MIs), secondary cancers (SCs) and autoimmune diseases (ADs) are the most common and relevant complications in patients with chronic lymphocytic leukaemia. METHODS: We performed a single-centre retrospective study to investigate the prevalence of the above quoted complications, the association with most important prognostic markers and their impact on survival (n = 795). RESULTS: Almost one out of three patients experienced at least one complication and only 0.9% of the cohort developed all three complications. One hundred and twenty (20%) subjects developed SC, 98 MI (12%) and 80 AD (10%); these complications seem to occur in a mutually exclusive manner. By Kaplan-Meier analysis we estimated that after 20 years from the diagnosis SC, MI and AD occurred in 48%, 42% and 29% of patients, respectively. Furthermore, we showed that some clinical and biological markers are skewed among patients with different complications and that subjects with MI and SC had a worse prognosis than those with AD and all other patients (p < 0.0001). CONCLUSIONS: This study reveals the existence of different clinical subsets of chronic lymphocytic leukaemia patients characterised by an increased and different risk for developing specifically MI, SC and AD.
BACKGROUND: Major infections (MIs), secondary cancers (SCs) and autoimmune diseases (ADs) are the most common and relevant complications in patients with chronic lymphocytic leukaemia. METHODS: We performed a single-centre retrospective study to investigate the prevalence of the above quoted complications, the association with most important prognostic markers and their impact on survival (n = 795). RESULTS: Almost one out of three patients experienced at least one complication and only 0.9% of the cohort developed all three complications. One hundred and twenty (20%) subjects developed SC, 98 MI (12%) and 80 AD (10%); these complications seem to occur in a mutually exclusive manner. By Kaplan-Meier analysis we estimated that after 20 years from the diagnosis SC, MI and AD occurred in 48%, 42% and 29% of patients, respectively. Furthermore, we showed that some clinical and biological markers are skewed among patients with different complications and that subjects with MI and SC had a worse prognosis than those with AD and all other patients (p < 0.0001). CONCLUSIONS: This study reveals the existence of different clinical subsets of chronic lymphocytic leukaemiapatients characterised by an increased and different risk for developing specifically MI, SC and AD.
Authors: Francesco Angotzi; Andrea Visentin; Federico Scarmozzino; Alessandro Cellini; Roberta Bertorelle; Marco Pizzi; Gianni Binotto; Angelo Paolo Dei Tos; Livio Trentin Journal: Curr Oncol Date: 2022-02-27 Impact factor: 3.677
Authors: Andrea Visentin; Laura Bonaldi; Gian Matteo Rigolin; Francesca Romana Mauro; Annalisa Martines; Federica Frezzato; Stefano Pravato; Leila Romano Gargarella; Maria Antonella Bardi; Maurizio Cavallari; Eleonora Volta; Francesco Cavazzini; Mauro Nanni; Monica Facco; Francesco Piazza; Anna Guarini; Robin Foà; Gianpietro Semenzato; Antonio Cuneo; Livio Trentin Journal: Haematologica Date: 2022-04-01 Impact factor: 9.941